Evaluating the impact of hypoxia on Lu-177 PSMA treatment in prostate cancer
Effect of 18F-Fluoromisonidazole (18F-FMISO) PET Imaging on Evaluation of Hypoxia Before Lu-177 PSMA Treatment for Prostate Cancer
This study is testing how low oxygen levels in tumors affect the success of a specific prostate cancer treatment called Lu-177 PSMA, to help doctors choose the best treatment for patients.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | Ankara University Academic / other |
| Drugs / interventions | Radiation |
| Locations | 1 site (Ankara) |
| Trial ID | NCT06433063 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the role of hypoxia in prostate cancer patients undergoing Lu-177 PSMA treatment by utilizing 18F-FMISO PET imaging. The research focuses on quantifying tumor hypoxia, which is known to influence the effectiveness of radiotherapy. By identifying hypoxic conditions prior to treatment, the study seeks to improve patient selection and treatment outcomes for those with metastatic prostate cancer. The findings could provide insights into the mechanisms of treatment resistance and enhance therapeutic strategies.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients diagnosed with prostate cancer who are being considered for Lu-177 PSMA treatment.
Not a fit: Patients with a life expectancy of less than 3 months or those with contraindications for Lu-177 PSMA treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment outcomes for prostate cancer patients by optimizing the use of Lu-177 PSMA therapy based on hypoxia levels.
How similar studies have performed: While there is ongoing research into the effects of hypoxia on cancer treatments, this specific approach using Lu-177 PSMA and 18F-FMISO PET imaging is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * over 18 years old * Patients diagnosed with prostate cancer who were referred to our clinic for Lu-177 PSMA treatment and were found suitable for treatment Exclusion Criteria: * Has a life expectancy of less than 3 months * ECOG\>2 * contraindication for radionuclide treatment with Lu-177 PSMA
Where this trial is running
Ankara
- Ankara University Medical School — Ankara, Turkey (Türkiye) (Recruiting)
Study contacts
- Study coordinator: Cigdem Soydal, Asc Prof
- Email: csoydal@yahoo.com
- Phone: +903125956732
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.